The text discusses various studies and guidelines related to non-metastatic colon cancer, including screening for vulnerability in older cancer patients, hereditary colorectal cancer syndromes, and the use of different treatment options such as oxaliplatin, fluorouracil, and leucovorin with or without cetuximab. It also highlights the prognostic and predictive value of circulating tumor DNA in determining adjuvant treatment duration for stage III colon cancer.